Danish Bhatti

Prof. Danish Bhatti


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2017 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
HGHoward Eliot Gendelman
Howard Eliot Gendelman
YZYuning Zhang
Yuning Zhang
PSPamela Santamaria
Pamela Santamaria
KOKatherine E. Olson
Katherine E. Olson
CSCharles R. Schutt
Charles R. Schutt
RMR. Lee Mosley
R. Lee Mosley
A potential therapeutic role for immune transformation in Parkinson’s disease evolves from more than a decade of animal investigations demonstrating regulatory T cell (Treg) nigrostriatal neuroprotection. To bridge these results to human disease, we conducted a randomized, placebo-controlled double-blind phase 1 trial with a well-studied immune modulator, sargramostim (granulocyte-macrophage colony-stimulating factor). We enrolled 17 age-matched non-Parkinsonian subjects as non-treated controls and 20 Parkinson’s disease patients. Both Parkinson’s disease patients and controls were monitored for 2 months for baseline profiling. Parkinson’s disease patients were then randomized into two equal groups to self-administer placebo (saline) or sargramostim subcutaneously at 6 μg/kg/day for 56 days. Adverse events for the sargramostim and placebo groups were 100% (10/10) and 80% (8/10), respectively. These included injection site reactions, increased total white cell counts, and upper extremity bone pain. One urticarial and one vasculitis reaction were found to be drug and benzyl alcohol related, respectively. An additional patient with a history of cerebrovascular disease suffered a stroke on study. Unified Parkinson’s disease rating scale, Part III scores in the sargramostim group showed modest improvement after 6 and 8 weeks of treatment when compared with placebo. This paralleled improved magnetoencephalography-recorded cortical motor activities and Treg numbers and function compared with pretreated Parkinson’s disease patients and non-Parkinsonian controls. Peripheral Treg transformation was linked to serum tryptophan metabolites, including L-kynurenine, quinolinic acid, and serotonin. These data offer a potential paradigm shift in modulating immune responses for potential therapeutic gain for Parkinson’s disease. Confirmation of these early study results requires larger numbers of enrolled patients and further clinical investigation.

12 September 2017 in Neurology
Verified
Journal Article
Closed access
PDF file
MFMichelle E. Fullard
Michelle E. Fullard
DTDylan P. Thibault
Dylan P. Thibault
AHAndrew Hill
Andrew Hill
JFJoellyn Fox
Joellyn Fox
DBDanish Bhatti
Danish Bhatti
AWAllison W. Willis
Allison W. Willis
Objective: To examine rehabilitation therapy utilization for Parkinson disease (PD). Methods: We identified 174,643 Medicare beneficiaries with a diagnosis of PD in 2007 and followed them through 2009. The main outcome measures were annual receipt of physical therapy (PT), occupational therapy (OT), or speech therapy (ST). Results: Outpatient rehabilitation fee-for-service use was low. In 2007, only 14.2% of individuals with PD had claims for PT or OT, and 14.6% for ST. Asian Americans were the highest users of PT/OT (18.4%) and ST (18.4%), followed by Caucasians (PT/OT 14.4%, ST 14.8%). African Americans had the lowest utilization (PT/OT 7.8%, ST 8.2%). Using logistic regression models that accounted for repeated measures, we found that African American patients (adjusted odds ratio [AOR] 0.63 for PT/OT, AOR 0.63 for ST) and Hispanic patients (AOR 0.97 for PT/OT, AOR 0.91 for ST) were less likely to have received therapies compared to Caucasian patients. Patients with PD with at least one neurologist visit per year were 43% more likely to have a claim for PT evaluation as compared to patients without neurologist care (AOR 1.43, 1.30–1.48), and this relationship was similar for OT evaluation, PT/OT treatment, and ST. Geographically, Western states had the greatest use of rehabilitation therapies, but provider supply did not correlate with utilization. Conclusions: This claims-based analysis suggests that rehabilitation therapy utilization among older patients with PD in the United States is lower than reported for countries with comparable health care infrastructure. Neurologist care is associated with rehabilitation therapy use; provider supply is not.

8 October 2017 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
PDF file
DBDanish Bhatti
Danish Bhatti
RTRebecca Thompson
Rebecca Thompson
AHAmy Hellman
Amy Hellman
CPCynthia Penke
Cynthia Penke
JBJohn M Bertoni
John M Bertoni
DTDiego Torres‐Russotto
Diego Torres‐Russotto

21 July 2018 in Current Treatment Options in Neurology
Verified
Journal Article
Closed access
PDF file
DWDavid Whitney
David Whitney
DBDanish Bhatti
Danish Bhatti
DTDiego Torres-Russotto
Diego Torres-Russotto

Verified
Open access
PDF file
ALAbhishek Lenka
Abhishek Lenka
PPPramod Kumar Pal
Pramod Kumar Pal
DBDanish Bhatti
Danish Bhatti
ELElan D. Louis
Elan D. Louis

1 February 2018 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
DBDanish Bhatti
Danish Bhatti
RTRebecca Thompson
Rebecca Thompson
YXYiwen Xia
Yiwen Xia
AMAmy Hellman, M.D.
Amy Hellman, M.D.
LSLorene Schmaderer
Lorene Schmaderer
DTDiego Torres-Russotto
Diego Torres-Russotto